Cellular senescence involves a stable cell-cycle arrest coupled to a secretory program that,
in some instances, stimulates the immune clearance of senescent cells. Using an immune …

Therapy induced senescence (TIS) in tumors and TIS cancer cells secrete proinflammatory
senescence-associated secretory phenotype (SASP) factors. SASP factors promote TIS …

In addition to promoting various forms of cell death, most conventional anti-tumor therapies
also promote senescence. There is now extensive evidence that therapy-induced …

On acquisition of an oncogenic mutation, primary human and mouse cells can enter
oncogene-induced senescence (OIS). OIS is characterized by a stable proliferation arrest …

Cellular senescence occurs in proliferating cells as a consequence of various triggers
including telomere shortening, DNA damage, and inappropriate expression of oncogenes …

Therapy-induced cellular senescence is a state of stable growth arrest induced by common
cancer treatments such as chemotherapy and radiation. In an oncogenic context, therapy …

Immune functions decline as we age, while the incidence of cancer rises. The advent of
immune checkpoint blockade (ICB) has not only revolutionized cancer therapy, but also …

Although initially described as the end state of cells after extended rounds of division in
culture, it is now clear that cellular senescence induced by different stimuli plays an …

Senescent cells within the tumor microenvironment (TME) adopt a proinflammatory,
senescence-associated secretory phenotype (SASP) that promotes cancer initiation …

Inflammation underlies most age-related diseases, including cancer, but the etiology is
poorly understood. One proposed factor is the presence of senescent cells, which increase …